Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo fundamental de N-acetil-L-leucina na ataxia-telangiectasia (AT)

2 de novembro de 2026 atualizado por: IntraBio Inc

Efeitos da N-acetil-L-Leucina na Ataxia-Telangiectasia (AT: um estudo de Fase III, randomizado, controlado por placebo, duplo-cego, cruzado

A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Visão geral do estudo

Status

Ativo, não recrutando

Descrição detalhada

This is a multinational, randomized, placebo-controlled, double-blinded, cross-over Phase III study that will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) versus Placebo for the treatment of Ataxia-Telangiectasia (A-T).

Patients will be assessed during three study periods: a baseline period (approximately 2-weeks), after which they will be randomized (1:1) to receive treatment with IB1001 or Placebo for approximately 12-weeks during the first intervention period ("Period I"). Following Period I, patients will crossover to receive the opposite treatment (IB1001 or Placebo) for approximately 12-weeks during a second intervention period ("Period II).

Patients will be assessed twice during each study period. Patients who have participated in the study may be offered the opportunity to roll over into an Extension Phase, which is planned to allow patients to have further access to IB1001.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Cologne, Alemanha, 50937
        • University of Cologne
      • Giessen, Alemanha, 35392
        • University of Giessen
      • Bratislava, Eslováquia, 814 99
        • Comenius University Bratislava
      • Košice, Eslováquia, 040 11
        • University Hospital L. Pasteur
      • Madrid, Espanha, 28046
        • Hospital Universitario La Paz
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • University of California Los Angeles
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • The University of Texas Health (UT Health)
      • Cambridge, Reino Unido
        • Royal Papworth Hospital
      • Nottingham, Reino Unido
        • University of Nottingham
      • Bern, Suíça, 3012
        • University of Bern

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

4 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 1. Written informed consent signed by the patient and/or their legal representative / parent/ impartial witness 2. Male or female aged ≥4 years with a genetically confirmed diagnosis of A-T at the time of signing informed consent.

    3. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose and confirm to continue through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in <1% failure rate when used consistently and correctly) 14 days prior to the first dose continuing through 28 days after the last dose:

    1. intrauterine device (IUD);
    2. surgical sterilization of the partner (vasectomy for 6 months minimum);
    3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal);
    4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable);
    5. intrauterine hormone releasing system (IUS);
    6. bilateral tubal occlusion. 4. Females of non-childbearing potential who have undergone one of the following sterilization procedures at least 6 months prior to the first dose:
    1. hysteroscopic sterilization;

    2. bilateral salpingectomy;

    3. hysterectomy;

    4. bilateral oophorectomy; OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory.

      5. Non-vasectomized male patient agrees to use a condom with spermicide during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male.

      6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last dose.

      7. Patients must fall within:

    1. A SARA score of 7 ≤ X ≤ 34 points (out of 40) AND
    2. Either:

    i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds.

    8. Weight ≥15 kg at screening. 9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of A-T, including those on the prohibited medication list. Non-prohibited medications/therapies, therapy, and physiotherapy) are permitted provided:

    1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results

    2. Patients have been on a stable dose/duration and type of therapy for at least 42 days before Visit 1 (Baseline 1)

    3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study.

      10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).

      Exclusion Criteria:

  • 1. Patients who have any known hypersensitivity or history of hypersensitivity to:

    1. Acetyl-Leucine (DL-, L-, D-) or derivatives.

    2. Excipients the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavor).

    3. Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavor, citric acid, microcrystalline cellulose, lactose, denatonium benzoate).

      2. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the investigator, Medical Monitor, and Sponsor, the washout period for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug.

      3. Patients with a physical or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments.

      4. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.

      5. Current or planned pregnancy or women who are breastfeeding. 6. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.

      7. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.

      8. Patients unwilling and/or not able to undergo a 42-day washout period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6.

    1. N-Acetyl-DL-Leucine (e.g. Tanganil®);
    2. N-Acetyl-L-Leucine (prohibited if not provided as IMP in the IB1001-303 trial);
    3. Sulfasalazine;
    4. Rosuvastatin.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: N-acetyl-L-leucine (IB1001)

Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients will receive a total daily dose of 2-4 g/day based on weight-tiered doses.

N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

Outros nomes:
  • IB1001
  • levacetilleucina
Comparador de Placebo: Placebo comparator

Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients will receive a total daily dose of 2-4 g/day based on weight-tiered doses.

Matching Placebo Sachet

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Scale for the Assessment and Rating of Ataxia
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

The Scale for Assessment and Rating of Ataxia has 8 items that are related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements, and heel-shin test. The range is 0-40 points, with a lower score representing neurological improvement and a higher score representing neurological worsening.

End of Period I (week 12) vs. End of Period 2 (week 24)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Spinocerebellar Ataxia Functional Index (SCAFI)
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

Spinocerebellar Ataxia Functional Index (SCAFI) is composed of 8 Meter Walk Test, 9-Hole Peg Test of Dominant and Non-Dominant Hand (9HPT-D/9HPT-ND) (the 3 tests are timed assessments; each is done twice and values are averaged; the 8MWT and 9HPT-D and 9HPT-ND values are converted from times to rates, and the results expressed as a composite Z-score of each test relative to baseline) and the PATA rate (counted number how often a patient can repeat the syllables "PATA" within 10 seconds), a measure of speech performance. The scores of these 3 were transformed to Z-scores (=individual's average of both trials to perform the respective task - mean of study population at baseline) / SD of study population at baseline). A Z-score of 0 equates to the population mean at baseline. For all 3, higher Z-scores (above mean) mean better performance. The SCAFI total score was calculated as the arithmetic mean of the non-missing Z-scores for the 3. A higher total score means better performance.

End of Period I (week 12) vs. End of Period 2 (week 24)
Physician's / Caregiver's / Patient's Clinical Global Impressions (CGI)
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

The Clinical Global Impression of Improvement assessed by the investigator/caregiver/patient is evaluated on a 7 point Likert scale ranging from 1='very much improved' to 7='very much worse'

End of Period I (week 12) vs. End of Period 2 (week 24)
EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

For posting, health-related quality of life based on the EQ-5D visual analogue scale (VAS) was presented as a secondary endpoint.

EQ-5D VAS is a 0-100 scale where patients are asked to indicate their overall health, with a score of 0 indicating worst health and a score of 100 indicating best health.

End of Period I (week 12) vs. End of Period 2 (week 24)
International Cooperate Ataxia Rating Scale (ICARS)
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

The International Cooperate Ataxia Rating Scale (ICARS) was developed to quantify the level of impairment as a result of ataxia as related to hereditary ataxias. Disorders rated as subscales within the ICARS are: Postural and gait disturbances, Limb Ataxia, Dysarthria, and Oculomotor disorders

End of Period I (week 12) vs. End of Period 2 (week 24)
Neuro Quality of Life - Upper Extremity Function (NeuroQOL-UEF)
Prazo: End of Period I (week 12) vs. End of Period 2 (week 24)

The Neurology Quality of Life (NeuroQOL) Upper Extremity Function (UEF) scale is a self-report of health-related quality of life that measures the patient's ability to carry out various activities involving digital, manual, and reach-related functions, ranging from fine motor to self-care (activities of daily living)

End of Period I (week 12) vs. End of Period 2 (week 24)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de março de 2025

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

31 de outubro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de novembro de 2024

Primeira postagem (Real)

4 de novembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

The results of the study will be published within a reasonable timeframe of completion. Pseudonymised individual patient data may be available in these findings.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever